Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing

The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2020-07, Vol.10 (1), p.12581-12581, Article 12581
Hauptverfasser: Nanki, Yoshiko, Chiyoda, Tatsuyuki, Hirasawa, Akira, Ookubo, Aki, Itoh, Manabu, Ueno, Masaru, Akahane, Tomoko, Kameyama, Kaori, Yamagami, Wataru, Kataoka, Fumio, Aoki, Daisuke
Format: Artikel
Sprache:eng
Schlagworte:
631/67/1517
631/67/1517/1709
631/67/70
Antineoplastic Agents - therapeutic use
BRCA1 protein
Cell culture
Copy number
Drug Resistance, Neoplasm - genetics
Drugs
Female
Genome, Human
Humanities and Social Sciences
Humans
multidisciplinary
Organoids
Organoids - drug effects
Ovarian cancer
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - genetics
Paclitaxel
Platinum
Poly(ADP-ribose) polymerase
Precision Medicine
Science
Science (multidisciplinary)
Sensitivity analysis
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The use of primary patient-derived organoids for drug sensitivity and resistance testing could play an important role in precision cancer medicine. We developed expandable ovarian cancer organoids in 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-69488-9